Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Recommendation of “Buy” from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $37.17.

A number of equities analysts have commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the sale, the chief financial officer now owns 23,382 shares of the company’s stock, valued at $540,124.20. The trade was a 27.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now directly owns 26,528 shares in the company, valued at $595,553.60. The trade was a 25.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,766 shares of company stock worth $2,011,735 in the last ninety days. 54.57% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth about $50,000. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $61,000. KLP Kapitalforvaltning AS bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $158,000. Bellevue Group AG bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $160,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock worth $168,000 after buying an additional 4,575 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Stock Up 2.1 %

NASDAQ:KNSA opened at $23.08 on Thursday. The business’s 50 day moving average is $20.16 and its two-hundred day moving average is $22.08. Kiniksa Pharmaceuticals has a 52 week low of $16.56 and a 52 week high of $28.15. The company has a market cap of $1.68 billion, a PE ratio of -164.85 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The firm had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.35 earnings per share. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.